Objective To observe the efficacy of osimertinib targeted therapy for advanced non-small cell lung can-cer(NSCLC)and its impact on serum tumor markers.Method A total of 79 NSCLC patients were divided into control group(n=40)and observation group(n=39)by drawing lots.The control group received pemetrexed+cisplatin chemother-apy,while the observation group received osimertinib targeted therapy on the basis of the control group.The clinical effi-cacy,serum tumor marker levels,and adverse reactions were compared between two groups.Result The total effective rate of the observation group was 76.92％,which was higher than 55.00％of the control group,the difference was statisti-cally significant(P＜0.05).After treatment,the levels of carcinoembryonic antigen(CEA),cyto-keratin 19 fragment anti-gen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of rash,leukopenia,diarrhea,and liver function damage in the observation group were lower than those in the control group,and the differences were statistical-ly significant(P＜0.05).Conclusion Osimertinib targeted treatment combined with chemotherapy in advanced NSCLC has a good effect,which can reduce serum tumor marker levels and incidence of adverse reactions.
万方数据
维普
